The treatment of choice by dermatologists is a safe and inexpensive oral medication,
griseofulvin, a secondary metabolite of the fungus
Penicillium griseofulvin. This compound is
fungistatic (inhibiting the growth or reproduction of fungi) and works by affecting the
microtubular system of fungi, interfering with the
mitotic spindle and cytoplasmic
microtubules. The recommended pediatric dosage is 10 mg/kg/day for 6–8 weeks, although this may be increased to 20 mg/kg/d for those infected by
T. tonsurans, or those who fail to respond to the initial 6 weeks of treatment. Unlike other fungal skin infections that may be treated with
topical therapies like creams applied directly to the affected area, griseofulvin must be taken orally to be effective; this allows the drug to penetrate the hair shaft where the fungus lives. The effective therapy rate of this treatment is generally high, in the range of 88–100%. Other oral antifungal treatments for tinea capitis also frequently reported in the literature include
terbinafine,
itraconazole, and
fluconazole; these drugs have the advantage of shorter treatment durations than griseofulvin. A 2016 meta-analysis of randomized controlled trials found that terbinafine, itraconazole and fluconazole were at least equally effective as griseofulvin for children infected with
Trichophyton, and terbinafine is more effective than griseofulvin for children with
T. tonsurans infection
. However, concerns have been raised about the possibility of rare side effects like
liver toxicity or interactions with other drugs; furthermore, the newer drug treatments tend to be more expensive than griseofulvin. On September 28, 2007, the U.S.
Food and Drug Administration stated that
Lamisil (
Terbinafine hydrochloride, by
Novartis AG) is a new
treatment approved for use by
children aged 4 years and older. The
antifungal granules can be sprinkled on a child's food to treat the infection. Lamisil carries hepatotoxic risk, and can cause a metallic taste in the mouth. ==Epidemiology==